Table 1.

Effect of EBRE on insulin, fasting plasma glucose levels, HOMA-IR, and HOMA-β in streptozotocin-induced diabetic rat. Results are expressed as mean ± SEM, n = 6.

Groups	Glucose (mg/dL)	Insulin (μIU/mL)	HOMA-IR	HOMA-β
Control	99.00 ± 6.30	2.70 ± 0.25	0.69 ± 0.09	156.06 ± 21.1 2
Diabetic	211.57 ± 10.7###	1.63 ± 0.13###	0.85 ± 0.08	0.42 ± 2.16###
Diabetic+ glibenclamide	132.16 ±9.38*	2.53 ± 0.14***	0.82 ± 0.06	72.26 ± 10.3###,*
Diabetic + EBRE (100 mg/kg)	118.80 ± 9.48***	2.84 ± 0.14***	0.84 ± 0.08	98.96 ± 11.2#, ***
Diabetic + EBRE (200 mg/kg)	197.40 ± 16.5###	2.40 ± 0.17	1.19 ± 0.15##	34.66 ± 4.84###
Diabetic + EBRE (400 mg/kg)	178.28 ± 12.1###	1.91 ± 0.17#	0.83 ± 0.07	34.31 ± 8.42###

EBRE, Eryngium billardieri root extract; HOMA-β, homeostatic model assessments of pancreatic β-cell function; HOMA-IR, homeostatic model assessment of insulin resistance. *P < 0.05 and ***P < 0.001 indicate significant differences compared to the diabetic group; #P < 0.05, ##P < 0.01, and ^###P < 0.001 versus control group.